Abstract
To verify whether serum tumor abnormal protein (TAP) would correlate with the responsiveness of palliative chemotherapy in patients with advanced gastric cancer, and the variation of conventional serum tumor markers e.g., carcinoembryonic antigen (CEA), antigen 125 (CA125),carbohydrate antigen19-9 (CA19-9) of adjuvant chemotherapy in patients with early gastric cancer. Patients with histologically confirmed gastric cancer and treated with chemotherapy were enrolled into this study. TAP values of these patients were determined by detecting abnormal sugar chain glycoprotein in serum, combined with the area of agglomerated particles. For patients with advanced gastric cancer, responsiveness of palliative chemotherapy was compared with variation of TAP and the relation between variation of TAP and tumor markers in patients with early gastric cancer was analyzed. Totally 82 gastric cancer patients were enrolled into this study. The value of TAP is more closely related to responsiveness of palliative chemotherapy for patients with advanced gastric cancer. The correlation between TAP and responsiveness to palliative chemotherapy is stronger than the correlation between several conventional serum tumor markers (CEA, CA125 and CA199) .The variation of TAP was also positively correlated with the trend of CA125 in adjuvant chemotherapy. TAP is sensitive in monitoring the responsiveness to palliative chemotherapy in patients with advanced gastric cancer. But this result should be confirmed by randomized clinical trials for patients with gastric cancer.
Highlights
Gastric cancer is one of the most common malignant tumors in China, and the morbidity and mortalit rate are still high in recent years (Jemal et al, 2006)
The correlation between Tumor abnormal protein (TAP) and responsiveness to palliative chemotherapy is stronger than the correlation between several conventional serum tumor markers (CEA, CA125 and carbohydrate antigen 19-9 (CA199)) .The variation of TAP was positively correlated with the trend of CA125 in adjuvant chemotherapy
All patients were divided into two groups, group A with early gastric cancer treated with adjuvant chemotherapy, Results and group B with advanced gastric cancer treated with palliative chemotherapy
Summary
Gastric cancer is one of the most common malignant tumors in China , and the morbidity and mortalit rate are still high in recent years (Jemal et al, 2006). A variety of abnormal sugar chain glycoprotein produced during the multistep development of human tumors (Dube et al, 2005). To verify whether serum tumor abnormal protein (TAP) would correlate with the responsiveness of palliative chemotherapy in patients with advanced gastric cancer, and the variation of conventional serum tumor markers e.g., carcinoembryonic antigen (CEA), antigen 125 (CA125),carbohydrate antigen (CA19-9) of adjuvant chemotherapy in patients with early gastric cancer. For patients with advanced gastric cancer, responsiveness of palliative chemotherapy was compared with variation of TAP and the relation between variation of TAP and tumor markers in patients with early gastric cancer was analyzed. Conclusions: TAP is sensitive in monitoring the responsiveness to palliative chemotherapy in patients with advanced gastric cancer This result should be confirmed by randomized clinical trials for patients with gastric cancer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
